Apellis Pharmaceuticals, Inc. 4

Mikael Dolsten tendered/converted 14,312 Apellis common shares and 24,135 in-the-money options into cash and CVRs as part of the Biogen merger on 2026-05-14.

On May 14, 2026, Mikael Dolsten reported the automatic disposition of his Apellis Pharmaceuticals, Inc. common stock and vested stock options in connection with the closing of the tender offer and subsequent merger with Biogen Inc. Under the merger agreement, 14,312 shares of Apellis common stock held by Dolsten were exchanged for $41.00 per share in cash plus one contingent value right (CVR) per share, and his vested in-the-money stock options covering 24,135 shares with a $20.96 exercise price were cancelled and converted into a cash payment equal to the spread between $41.00 and $20.96 per share plus one CVR for each underlying share. These transactions resulted in Dolsten ceasing to own Apellis common stock directly, with his former equity interests converted into cash and CVR entitlements, reflecting a change-of-control clean-up rather than discretionary open-market trading.

Filing Facts

CIK

1492422

Ticker

APLS

Form

4

Source Type

sec

Accession

0001193125-26-224624

Alert Tier

6